Awesome step from FDA for approving a drug that targets particular genetic mutations, instead of a specific cancer. Great approach from Loxo for this groundbreaking approach and innovation. The human trial results have been impressive with 81% response rate and 17% complete response (went cancer-free) out of 109 subjects. #innovation #healthcare #FDA …see more